Retatrutide is investigational, so its full safety profile is still being established in Phase 3. The effects below come from published Phase 2 data and are not a complete or final list.
Most commonly reported effects
As with other incretin medications, the most frequent effects in trials were gastrointestinal:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Reduced appetite (the intended effect, but it can be pronounced)
These were generally mild-to-moderate and most likely during the first weeks and around each dose increase. Higher studied doses (8–12 mg) tended to produce more GI effects than lower ones.
Why slow titration matters
Trials raised the dose gradually — roughly every four weeks — specifically to let the gut adapt and reduce nausea. Rushing the dose is the single most common reason people experience severe GI effects. See the retatrutide dosage chart for the escalation studied.
Other considerations
Incretin drugs as a class carry labeled warnings around gallbladder issues, pancreatitis, and (in animal studies) thyroid C-cell tumors. Because retatrutide is unapproved, there is no FDA-reviewed warning label, and products sold online as “research” retatrutide are unregulated and not quality-assured. Any use should be discussed with a licensed clinician.
Important: retatrutide is not FDA-approved
Retatrutide is still in Phase 3 trials and cannot be legally prescribed or sold as a finished drug in the U.S. If you want a clinician-supervised, FDA-approved GLP-1 for weight loss today, a licensed telehealth provider can assess whether semaglutide or tirzepatide is right for you.
See FDA-approved options →Find a retatrutide trialFrequently asked questions
What are the most common retatrutide side effects?
Does retatrutide cause hair loss?
How do you reduce retatrutide side effects?
Dose with confidence — free tips by email
Practical dosing guides, reconstitution tips, and ways to save on your meds — about once a week, no fluff.